Liraglutide belongs to the GLP-1 receptor agonist class of drug, and current prescribing information for liraglutide products used in long-term weight management uses that 0.6 mg to 3 mg step-up schedule
Retatrutide does it via GLP-1 receptor activation in the gut and CNS
S., Alothaid, H., Bantun, F., Alhazmi, A., Hakamy, A., Kaabi, Y
Any switch should be clinician-directed
Standard Cagrilintide Monotherapy Chart CAGRILINTIDE ESCALATION PROTOCOL Week 1-4: [0.6 mg] Tolerance Assessment Week 5-8: [1.2 mg] Efficacy & Safety Review Week 9+: [2.4 mg] Maintenance Monitoring Theoretical Combination Dosing Chart For cagrilintide dosage with tirzepatide , a theoretical combination chart might look like: COMBINATION PROTOCOL (THEORETICAL) TIRZEPATIDE CAGRILINTIDE Week 1-4: 2.5 mg None Week 5-8: 5.0 mg None Week 9-12: 7.5 mg None Week 13-16: 7.5 mg 0.6 mg Introduction Week 17-20: 10 mg 1.2 mg Week 21+: 12.5 mg 2.4 mg Optimization This staged approach minimizes the risk of overwhelming gastrointestinal side effects while allowing for individualized dose optimization
A method of reversing, ameliorating or slowing progression of at least one symptom of Lewy body pathology in a patient in need thereof, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to reverse, ameliorate or slow progression of said at least one symptom, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 wherein Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
